Recent Articles from Investor Brand Network

Polyrizon (NASDAQ: PLRZ), a biotech company specializing in innovative intranasal hydrogels, has closed its previously announced private placement of approximately $17.0 million ordinary shares and/or pre-funded and investor warrants at a price of $0.48 per ordinary unit. The company secured approximately $17.0 million in aggregate gross proceeds from the offering and intends to use the net, together with its existing cash, for general corporate purposes and working capital. Aegis Capital Corp. acted as exclusive placement agent for the private placement. Greenberg Traurig, P.A. acted as counsel to the company, and Kaufman & Canoles, P.C. acted as counsel to Aegis.

IBN (“InvestorBrandNetwork”), an innovative corporate communications firm and content distributor, has announced its collaboration with Centri Business Consulting, LLC for the upcoming Centri Capital Conference . The event, set to take place at Nasdaq in New York City on April 22, 2025, will feature carefully selected companies, distinguished speakers, fireside chats, and interactive industry panels. As a media sponsor, IBN will leverage its extensive corporate communications solutions to enhance the visibility of the conference across multiple digital channels.

Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ), doing business as Medcana, has completed its first international export of pharmaceutical-grade CBD flower through Colombian partner Anutea S.A.S., marking a significant step in its global expansion strategy. The shipment to Switzerland delivered 18 kilograms of premium CBD—well above the projected 10 kilograms—and generated approximately $2,500 in initial revenue. The company highlighted this milestone as proof of its operational readiness, regulatory compliance, and growing international demand. With additional buyers already secured and a 58,000-square-foot greenhouse nearing completion, Software Effective Solutions is positioning for larger export volumes in the near future.

Quant Strats USA 2025, held on March 11 at Quorum by Convene in New York, brought together over 380 professionals in quantitative finance, with 70% of attendees representing the Buy-Side, including hedge funds, asset managers, and investment banks. The event reaffirmed its role as a premier forum for exploring advancements in artificial intelligence (“AI”), machine learning (“ML”), and large language models (“LLMs”) within finance, offering attendees unparalleled access to industry-leading insights and networking opportunities.

KRTL HOLDING Group (OTC: KRTL), a diversified holding company focused on biotechnology innovation, global API sourcing, and cross-border distribution solutions, has commenced trading on Upstream under ticker symbol KRTL. “We are thrilled to dual list on Upstream’s next-generation marketplace. This milestone supports our mission to drive innovation and expand across the global environment by securing FDA-compliant supply chains and ensuring the availability of critical healthcare inputs in the U.S. market under the highest regulatory standards,” said Cesar Herrera, CEO of KRTL.

SOBRsafe (NASDAQ: SOBR) provider of next-generation transdermal alcohol detection solutions, will implement a 1-for-10 reverse stock split effective at 12:01 a.m. ET on April 4, 2025, following board approval and prior shareholder authorization. Post-split trading will begin the same day under the existing ticker with a new CUSIP number. The split will reduce outstanding shares from roughly 15.2 million to approximately 1.5 million, with all shareholders maintaining their proportional ownership. Fractional shares will be rounded up, and all related securities such as warrants and equity awards will be proportionally adjusted. Equiniti Trust Company, LLC will manage the exchange process.

Nightfood Holdings (OTCQB: NGTF), an emerging player in AI-powered hospitality automation, has closed its acquisition of S W C Holdings, known as Carryout Supplies, a top provider of customized disposable packaging solutions. This move follows the company’s recent acquisition of Skytech Automated Solutions and positions Nightfood as a fully integrated solutions provider, combining robotics, packaging, and automation to streamline operations across hotels and foodservice. The addition of Carryout Supplies expands Nightfood’s recurring revenue base and access to key North American hospitality clients.

In a groundbreaking advancement for quantum technology, researchers have developed a quantum algorithm that allows quantum computers to analyze and preserve quantum entanglement—the very phenomenon that supports their power. This breakthrough, introduced by scientists from Tohoku University in Japan and St. Paul’s School in London, could significantly enhance the reliability and efficiency of quantum computing.

A research team from the University of Pittsburgh School of Medicine and UPMC Children’s Hospital of Pittsburgh has developed a new diagnostic tool capable of profiling brain cancers in pediatric patients. Composed of pediatric neurosurgeons and researchers, the team designed a diagnostic platform that uses the body’s natural cancer-fighting immune response to classify pediatric brain tumors.

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), will participate in the upcoming Jones Las Vegas Technology and Innovation Conference at The Venetian Resort. The April 8-9 event, organized by JonesTrading and supported by B2i Digital, provides a platform for direct engagement between innovative companies and institutional investors ( https://ibn.fm/fIKDc ).

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biopharmaceutical company with marketed products and a robust development pipeline, announced that CEO Seth Lederman, M.D., will present at the 2025 Jones Trading Healthcare and Innovation Conference. The presentation is scheduled for Wednesday, April 9, at 10 a.m. PT in Las Vegas.

Aditxt (NASDAQ: ADTX), a social innovation platform accelerating health breakthroughs, announced that Don Cilla, Pharm.D., M.B.A., CEO of Appili Therapeutics, will join its Weekly Update on April 4 at 11:30 a.m. ET. The session will spotlight the growing need for infectious disease treatments and explore how partnerships like Aditxt and Appili’s can fast-track health innovations. The discussion will also detail Appili’s $33.2 million in non-dilutive funding, $117 million in new applications, and updates to its U.S. Air Force Academy agreement supporting ATI-1701, a biodefense vaccine candidate.

The ZJ Alternative Products Expo will be held from April 3-5, 2025, at the Mana Wynwood Convention Center in Miami. The expo showcases the latest trends and the finest products and services of the counterculture community, tapping a worldwide audience. With Miami emerging as the epicenter of flavors, cultures, and smoke shops, the event aims to blend the local flavor of Florida with the rest of America.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted immunotherapies, reported a reduced net loss of $4.1 million for Q4 2024, down from $8.2 million the prior year. The company highlighted significant progress across its three oncology platforms, including the IND filing for CLD-201 targeting solid tumors and continued clinical development of CLD-101 for high-grade glioma. Preclinical data on its CLD-400 platform showed complete tumor eradication in some models. Research and development expenses fell to $1.8 million from $4.0 million year over year, while full-year net loss narrowed to $23.8 million. Calidi ended 2024 with $9.6 million in cash.

Pennsylvania lawmakers are stepping up their scrutiny of the state’s medical cannabis program following investigative reports by Spotlight PA.

Capstone Holding Corp. (NASDAQ: CAPS), a national building products distribution company that has successfully grown its business organically and through well-timed acquisitions, reported over 8% year-over-year revenue growth for its primary operating subsidiary, Instone, in the fourth quarter of 2024, as the company sets its sights on reaching a $100 million revenue run rate and at least $10 million in adjusted EBITDA by the end of 2025. CEO Matt Lipman emphasized the company’s commitment to doubling the business through strategic acquisitions, supported by favorable deal structures and multiple tuck-in and sister company opportunities under review. Operational highlights include the launch of Toro Stone across six states, strengthened gross margins through cost reductions, and continued national expansion in the building products sector.

The Alternative Products Expo (“Alt Pro Expo”), a production of ZJ Events, is returning to Miami at the Miami Expo 2025 . The event is set to take the stage at the dynamic and innovative Mana Wynwood Convention Center from April 3-5. “The Alternative Products Expo – Miami Expo is the leading B2B-only event in the counterculture industry and is a hub for driving market awareness, showcasing innovation, and building collaborative professional networks,” said Director of Partnerships Sebastian Carmona. “As the industry flagship expo for smoke shop professionals, we’re thrilled to return to Miami—a city with deep historical and cultural ties to South America. This three-day event welcomes industry veterans, established professionals and passionate entrepreneurs.”

Fifty 1 Labs (OTC: FITY), a forward-thinking leader in biotechnology and health innovation, today announced a groundbreaking achievement by its recently acquired subsidiary, Genetic Networks, in space-based biotechnology. The milestone stems from over a decade of space-based functional genomics from Dr. Corey Nislow’s laboratory, with the work highlighting the pivotal role of functional genomics in diverse aspects of human health and wellness. According to Dr. Nislow, the experiment findings have the potential to unlock new pathways for pharmaceutical development and human health in space exploration.

Knightscope (NASDAQ: KSCP), a developer of autonomous security robots and AI-driven technologies, reported $10.8 million in revenue for fiscal 2024, down from $12.8 million in 2023 due to product line restructuring. Despite a net loss of $31.7 million, the company strengthened its cash position to $11.1 million through $34.5 million in capital raises. Knightscope achieved major milestones including FedRAMP Authority to Operate, its first K5 GOV deployment at the Department of Veterans Affairs, and a U.S. Air Force SBIR contract. The company is progressing new ASR models and deepening its federal sales strategy to drive long-term growth.

Emperor Metals (CSE: AUOZ) (OTCQB: EMAUF) (FRA: 9NH) has retained APEX Geoscience Ltd. to conduct a Maiden Mineral Resource Estimate for its Duquesne West Gold Project in Quebec. The assessment will incorporate historic and recent drilling data, unsampled core, and AI-assisted modeling, with results expected in early Q2 2025. Emperor’s 2024 drilling prioritized near-surface, open-pit targets to rapidly build ounces, supported by a reinterpretation of the deposit using machine learning. The project currently hosts a historical inferred resource of 727,000 ounces at 5.42 g/t Au.

Datavault AI (NASDAQ: DVLT), a leader in AI-powered data monetization and valuation, issued a shareholder letter outlining a $40–50 million revenue goal for 2026 and disclosed $15 million in secured convertible debt financing. Proceeds will support strategic initiatives including IP portfolio expansion and asset acquisitions from CompuSystems. The company also spotlighted its presence at CES 2025 and partnerships with NYIAX, IBM, and Dolby, positioning itself at the forefront of Web 3.0 technologies. A business update call is scheduled for April 3, 2025, at 11:00 a.m. ET.

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FSE: GDT0), a Swiss-hosted cybersecurity and privacy communications provider, announced a non-brokered private placement to raise up to CA$1.4 million (US$1 million). The offering includes up to 40,000,000 units priced at CA$0.035 each, with each unit consisting of one common share and one full warrant exercisable at CA$0.05 for 24 months. Proceeds will support U.S. marketing efforts for Sekur’s privacy solutions and general working capital needs.

Thumzup (NASDAQ: TZUP), a rising AdTech player in social media branding and programmatic marketing, announced it has exceeded 800 advertisers on its platform, with expectations to cross 1,000 by mid Q2 2025. The company reported a 243% compound annual growth rate, fueled by strategic expansion into South Florida, Miami, and Greater Salt Lake City. Thumzup’s platform integrates with major social networks, including Instagram Reels and X, reaching over 535 million users monthly.

Nightfood Holdings (OTCQB: NGTF), an innovator in hospitality automation, has acquired Skytech Automated Solutions, Inc., a leader in AI-driven service technologies for hotels. This strategic move follows Nightfood’s recent acquisition of Carryout Supplies and enhances its Robotics-as-a-Service (RaaS) offerings. Skytech’s Laundry Helper robot, already in use at multiple hotel properties, will now be integrated into Nightfood’s broader automation platform to improve operational efficiency and guest experience. The combined capabilities are expected to boost market reach, recurring revenue, and operational scalability.

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., has announced the sale and related construction contract for the 3.26 MW Camillus Solar Project for Solar Advocate Development LLC in a deal valued at $7.3 million USD ( https://ibn.fm/qFjN7 ).

XTI Aerospace (NASDAQ: XTIA), a developer of vertical takeoff and landing (“VTOL”) aircraft, has closed a public offering of 2,941,200 shares of common stock (or pre-funded warrants) and an equal number of accompanying warrants at a combined offering price of $1.36 per unit. The five-year warrants are immediately exercisable at the same price. Gross proceeds totaled approximately $4 million before expenses, which the company will use for general working capital and to repay outstanding secured promissory notes.

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company targeting brain and CNS cancers, reported a full-year 2024 net loss of $14.9 million, down from $18.9 million in 2023, due to reduced R&D spending. Despite Berubicin missing its primary endpoint in a glioblastoma multiforme (GBM) trial, the drug demonstrated safety and comparable efficacy, guiding future analysis. The company is shifting focus to TPI 287, a candidate with orphan drug designation and prior clinical data. With $6.5 million in cash at year-end and an additional $9.9 million raised post-period, CNS expects funding to last through Q1 2026.

Nissan Motor is set to unveil a crossover version of the Nissan Leaf EV with an impressive 373-mile range. The Japanese automaker recently released teaser images of the updated electric vehicle, dubbed the 2026 Leaf, but has not yet revealed major details about the forthcoming update to its iconic Nissan Leaf EV.

The price of gold has risen significantly over the last couple of weeks, trading at $3077.30 per ounce by the end of last week. Thus far this month, the metal’s price has risen by 8%, with analysts expecting that it could end the quarter with a 17% increase.

Cutaneous melanoma is the most aggressive skin cancer type and it is characterized by manifesting diverse mutations. Under normal circumstances, several of these mutations could be identified as threats by the immune system, but in this type of cancer, this doesn’t happen . Consequently, most patients are unresponsive to immunotherapy. This challenge has baffled oncology researchers for years.

Elon Musk recently announced that his AI company, xAI, has acquired X, the social media platform he bought in 2022. The sale, which includes $12 billion in debt, is worth $45 billion, marginally more than Musk’s initial purchase price.

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases like ALS and MS, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025, at 11:30 a.m. PT. The event will be held at the Venetian Resort in Las Vegas and include 1×1 investor meetings. A webcast of the presentation will be available via the events section of Clene’s website.

The MoneyShow Masters Symposium will be held in Dallas from April 4 to 5, 2025, and it will be an exclusive event that brings together high-net-worth investors and top experts in the field of finance. This two-day symposium will provide a robust platform for investors to learn from world-renowned fundamental and technical analysts, professional traders, and global market strategists.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted immunotherapies, closed its previously announced registered direct offering and concurrent private placement with a single institutional investor, raising approximately $3.9 million in gross proceeds. The offering included 3,325,000 shares of common stock and pre-funded warrants for 2,728,000 shares, along with Series G warrants for 6,053,000 shares. Proceeds will support working capital and advance Calidi’s clinical and preclinical cancer therapy programs.

Wheaton Precious Metals (NYSE: WPM) (TSX: WPM) filed its Form 40-F with the SEC, including audited financial statements for 2024, now available via EDGAR and the company’s website. The company also announced it will host its Annual and Special Meeting of Shareholders on May 9, 2025, at 10:30 a.m. PT. Shareholders may attend in person at Wheaton’s Vancouver office or virtually via the provided TSX Trust platform. Registered shareholders and proxyholders will be able to vote and participate online using their control numbers and the password “wheaton2025.”

Quantum BioPharma (NASDAQ: QNTM) a biopharmaceutical company advancing innovative biotech assets, announced a joint clinical study with Massachusetts General Hospital to evaluate a novel PET imaging technique for tracking myelin integrity in multiple sclerosis (MS) patients. The study will assess [18F]3F4AP PET scans as a biomarker for demyelination, complementing MRI scans in both progressive and relapsing-remitting MS. The technique may enhance diagnostics in trials involving remyelinating and neuroprotective drugs, including Quantum’s Lucid-MS, which has shown promise in preserving the myelin sheath in preclinical models.

Tonix Pharmaceuticals (NASDAQ: TNXP), a biopharmaceutical company advancing innovative therapies, announced the launch of TONIX ONE , a fully integrated digital platform designed to streamline migraine care. Built through partnerships with UpScript Telemedicine, ProModRx, Blink Health, and a leading symptom-tracking app, TONIX ONE connects patients with migraine specialists, facilitates e-prescriptions, and accelerates treatment access. The platform offers educational tools and real-time support to help patients overcome treatment barriers and improve care outcomes.

The 5th PRC Performance Optimization Summit by DGE will be held in Philadelphia on April 29-30, 2025. DGE invites industry professionals to discuss compliance and the expertise needed to get the best regulatory results for advertising/promotional material.

Taking advantage of climate science may be the key to addressing climate change’s impact on green energy production and ensuring the world has a reliable supply of clean energy. Climate science refers to the study of climatic conditions, how they change over time, and how they are influenced by human and natural factors.

The Justice Department (DOJ) announced on March 27 that it was seeking to recover roughly $23 million in crypto assets after crypto financial service firm Gotbit and its CEO and founder, Aleksei Andriunin, pleaded guilty to financial misconduct.

U.S. President Donald Trump is expanding his presence in the world of cryptocurrency. His latest move includes the introduction of a new stablecoin called USD1. This digital currency, launched by World Liberty Financial, is designed to be equal in value to the U.S. dollar. The goal is to provide a reliable digital asset that businesses and investors can use for secure transactions.

Brera Holdings (NASDAQ: BREA), an Ireland-based company advancing a multi-club ownership model in global football, celebrated the legacy of Advisory Board member and former Italy international Giuseppe Rossi during Fiorentina’s Pepito Day on March 22 in Florence. The tribute at Stadio Artemio Franchi featured tributes from fans, football legends, and Rossi’s former coaches, recognizing his career-defining moments and contributions to the sport. Brera’s executive team and investors attended both the match and a gala in Rossi’s honor, reflecting his ongoing influence on the company’s community-first strategy.

According to statistics from Viridian Capital Advisors, a data analytics and investment banking firm based in New York, there was a 33% drop in the value of mergers and acquisitions (M&A) from the $1.74bn in 2023 to the $1.16bn registered last year. Frank Colombo, the MD of Viridian discussed a number of factors that could explain this trend.

MoneyShow, a leading producer of live and online financial conferences for investors, traders, and financial advisors, has announced the upcoming “ Income, Growth, and Value Virtual Expo ,” which is slated to take place on Apr. 29-30, 2025. “Markets have experienced increased volatility due to the announcement of sweeping tariffs, retaliatory measures from trading partners, stubborn inflation metrics, and more. However, the tumult in the markets and risk-off sentiment also presents unique and new opportunities for investors to earn higher yields and robust potential returns,” said MoneyShow’s Editor-in-Chief Mike Larson. “Our lineup of speakers includes veteran investors, highly successful traders, and renowned financial experts. They will share up-to-date insights to help attendees optimize their portfolios for growth – and protect against macroeconomic headwinds throughout 2025.”

IBN (“InvestorBrandNetwork”), an innovative corporate communications firm and content distributor, today announced its collaboration with ZJ Events LLC as the media sponsor in 2025 for the multi-location Alternative Products Expo (“Alt Pro Expo”) series across North, Latin and South America and the BizCann Expo in Medellin, Colombia. For these events, IBN will leverage sophisticated communications tools to optimize virtual coverage and broadcast live updates to more than 2 million social media followers across a variety of platforms.

Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining attention as it advances TNX-102 SL, a non-opioid investigational therapy for fibromyalgia, toward potential FDA approval by Aug. 15, 2025. The drug, designed to treat chronic pain and sleep disturbances without addiction risks, targets widespread pain and fatigue associated with fibromyalgia—an area where existing treatments like Cymbalta and Lyrica have left many patients dissatisfied. With a sublingual bedtime dose and potential applicability to Long COVID-related pain, TNX-102 SL could offer a scalable alternative in a chronic pain drug market projected to top $115 billion by 2031.

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced completion of the safety lead-in for its Phase 2 trial evaluating ENV105 in combination with apalutamide for metastatic, castration-resistant prostate cancer. The trial will now proceed with patient randomization to assess apalutamide alone versus the combination therapy. Safety and efficacy data from the lead-in phase are expected in the first half of 2025. The company is also validating biomarkers to identify patients most likely to benefit from ENV105 and continues enrollment at cancer centers in Los Angeles and Salt Lake City.

Mullen Automotive (NASDAQ: MULN), an electric vehicle manufacturer, announced a key legal victory after a federal court denied a motion to dismiss its spoofing lawsuit against IMC Financial Markets, Clear Street Markets LLC, UBS Securities LLC, and others. The lawsuit alleges that defendants used high-frequency algorithmic trading tactics—including “Baiting Orders”—to manipulate Mullen’s stock price between Nov. 2021 and Nov. 2023. The court found sufficient evidence that defendants placed and canceled large volumes of sell orders to artificially depress prices, harming Mullen and its shareholders. The case will now proceed to discovery.

The financial landscape is rapidly evolving, with private credit and alternative lending markets emerging as key drivers of growth and innovation. As traditional banking institutions tighten their lending criteria and businesses seek more flexible financing solutions, the demand for alternative lending options, such as FAVO Capital (OTC: FAVO), continues to soar.

Mullen Automotive (NASDAQ: MULN), an electric vehicle manufacturer, announced a key legal victory after a federal court denied a motion to dismiss its spoofing lawsuit against IMC Financial Markets, Clear Street Markets LLC, UBS Securities LLC, and others. The lawsuit alleges that defendants used high-frequency algorithmic trading tactics—including “Baiting Orders”—to manipulate Mullen’s stock price between Nov. 2021 and Nov. 2023. The court found sufficient evidence that defendants placed and canceled large volumes of sell orders to artificially depress prices, harming Mullen and its shareholders. The case will now proceed to discovery.

GivBux (OTC: GBUX), a publicly traded Super App and charitable giving platform, announced plans to sell a 30% equity stake for $212 million through a non-dilutive transaction aimed at preserving shareholder value. Proceeds will be invested in an income-focused strategy led by a private credit asset manager specializing in real estate, with the goal of generating steady cash flow to fuel the company’s platform expansion. The majority shareholder has agreed to retire a portion of shares to further reduce potential dilution.

Social media managers are a vital cog in the marketing team of any company and how well they perform their job can adversely or positively impact the rate at which account visitors are converted into customers while also boosting ROI. We discuss some of the key roles that your social media manager should perform in order for your business to benefit from this individual.

Under normal circumstances, natural killer cells in the body can detect and eliminate malignant cells. However, these NK cells can at times be unable to breach the defense mechanisms of tumors, rendering the killer cells unable to combat the growing cancer.

As venture debt enters a pivotal phase in 2025, investors are faced with a more complex and volatile lending environment. The shifting dynamics, influenced by rising interest rates and the unprecedented collapse of Silicon Valley Bank, demand a much more sophisticated approach to risk management. While venture debt continues to serve as an essential source of capital for startups, understanding the intricate challenges of the current landscape is crucial for navigating this evolving market.

Quantum BioPharma (NASDAQ: QNTM) a biopharmaceutical company, announced the closing of its final tranche in a debenture unit offering, raising a total of CAD $5 million. Proceeds will support research and development, commercialization efforts, and working capital, with management stating the funding provides runway through the first quarter of 2027. The company also began developing a hospital-use formulation of rekvry, its alcohol misuse treatment designed to alleviate healthcare system strain.

While many investors may be mesmerized by the surging price of gold, another metal, copper, is having its own bull run . Copper prices in New York reached a record-setting $5.24 for a pound of the metal after news reports suggested that President Trump was poised to slap import tariffs on copper within a few weeks. Markets had expected this action to occur much later in the year.

The Alternative Products Expo successfully wrapped up its 2025 event in Medellín, Colombia, on March 1-2, reinforcing its position as a premier gathering for the counterculture industry. This year’s event brought together thousands of attendees, including leading manufacturers, retailers, wholesalers, entrepreneurs, and industry pioneers, to explore innovations, foster connections, and capitalize on emerging market opportunities.

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FSE: GDT0), a Swiss-hosted cybersecurity and privacy communications platform, announced the closing of the final tranche of its non-brokered private placement, raising gross proceeds of CA$237,106. The offering included 6,973,705 units priced at CA$0.034, each consisting of one common share and one full warrant exercisable at CA$0.055 for 24 months. Company insiders, including the CEO, CFO and a board member, collectively purchased 2,050,000 units. Proceeds will be used to expand U.S. marketing efforts and support general corporate purposes.

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) has announced plans to develop a 7.2 MW DC ground-mount solar power project known as the Hoadley Hill Rd project (the “Project”) on a site located in upstate New York. According to the announcement, the Project is another key addition to SolarBank’s expanding development pipeline—which exceeds one gigawatt—as well as the company’s commitment to advancing community solar. Assuming receipt of the requested interconnection approval, SolarBank will continue efforts to complete the permitting process and secure necessary financing for construction of the Project. The Project is expected to be eligible for incentives under the New York State Energy Research and Development Authority (“NYSERDA”) NY-Sun Program.

Titan Partners Group, a division of American Capital Partners LLC, is acting as sole bookrunner for an underwritten offering of Genelux Corporation (NASDAQ: GNLX) , a late clinical-stage immuno-oncology company. Genelux recently announced pricing of the offering, which consists of 3,000,000 shares of its common stock, each at an offering price of $3.50. Genelux expects approximately $10.5 million in gross proceeds from the offering, of which it intends to use the net for working capital and general corporate purposes, including the continued clinical development of Olvi-Vec.

Upstream published a blog today that discussed ongoing efforts to enhance the trading experience via its innovative platform. The latest upgrade to Upstream’s KYC (Know Your Customer) identity verification process makes it more intuitive and seamless for users. The redesigned interface ensures a smoother experience while maintaining quick and secure verification, which is essential for preventing fraud and illicit activity. Users are prompted to complete KYC once their account balance reaches $500 or when withdrawing funds, though they can initiate verification at any time through the profile settings. Verification can take as little as 15 minutes or up to two business days, and once approved, users can easily fund, withdraw, and trade. Upstream ensures the safeguarding of personal data by securely storing information and adhering to strict data protection regulations.

Access to capital has long been the lifeline of small and medium-sized businesses (“SMBs”), but today, that lifeline is fraying. Rising interest rates, stricter lending practices, and ongoing banking instability have turned what was once an accessible stream of funding into a nearly insurmountable challenge. The landscape has changed dramatically from just a few years ago when government stimulus programs and looser lending standards made capital readily available. Now, small business owners are facing one of the toughest financial climates in recent history, with significant implications for employment, salaries, and overall economic stability.

Healthcare providers often struggle with complex reimbursement structures, making it difficult to optimize cash flow while ensuring high-quality value-based patient care. Adageis is a forward-thinking healthcare technology company reshaping patient care through flexible AI-centric software solutions for healthcare organizations. The company is able to simplify this process with its AI-powered ProActive Care Platform, a fintech solution designed to make it easy for providers to access the highest-value services available.

Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) approach, is committed to supporting grassroots football and expanding opportunities for young athletes, with the Juve Stabia Academy being a prime example. This initiative looks to tap into talent early, a tried-and-tested approach to creating new opportunities for youth players while also strengthening football communities in Italy and worldwide.

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted in a recent Zacks Small-Cap Research report that presented a favorable analysis, emphasizing the company’s advancements in vaccine and photodynamic therapy technologies.

Chinese battery electric vehicle (BEV) manufacturer BYD has once again outpaced Tesla in global electric vehicle sales. A recent financial report from the Shenzhen-based automaker revealed that BYD’s revenue surged by 29% in 2024, reaching an impressive $14.8 billion—eclipsing Tesla’s reported revenue of $13.5 billion for the same period.

Goldman Sachs increased its forecast for the price of gold indicating that it could reach $3,300 for every ounce by the close of this year. To back their revised prediction, the bank mentioned the increasing investment inflows into gold ETFs and the surging gold purchases of central banks around the world.

A recently published report indicates that the rate at which Medicare Advantage plans are growing is slowing down. The report was authored by HealthScape Advisors, a consulting company, together with Chartis, a healthcare advisory company.

The General Services Administration (GSA) is introducing a new artificial intelligence tool to assist its employees in their daily tasks.

Quantum BioPharma (NASDAQ: QNTM) reported its financial results for the fourth quarter and year ended Dec. 31, 2024, highlighting a strengthened balance sheet and strategic advances across its clinical programs. The company removed its Material Uncertainty Related to Going Concern, with $12.1 million in cash and a 36% reduction in net cash used for operations year over year. Operating expenses dropped over 32% to $16.1 million, while net loss narrowed 18% to $14.9 million. Quantum completed a clinical trial for its unbuzzd alcohol detox supplement, which showed a 40% faster reduction in blood alcohol concentration among participants. unbuzzd is now expanding through a master distribution agreement across Latin America and ongoing U.S. sales. The company also completed a Phase 1 trial of its multiple sclerosis treatment Lucid-MS, which was deemed safe and well-tolerated, with Phase 2 preparations underway. Other initiatives included a dual listing on Upstream, crypto treasury diversification, and the early development of rekvry, an alcohol misuse treatment for emergency settings.

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, reported recent activity at major scientific gatherings and announced upcoming conference appearances. The company presented research on its GITR agonist KROS 101 at the Society for Immunotherapy of Cancer Spring Meeting on March 12, participated in BIO Europe from March 17 to 19, and will attend the Fierce Pharma Engage meeting in San Diego from April 29 to May 1. An abstract has also been accepted for presentation at the American Society of Clinical Oncology Annual Meeting in Chicago from May 20 to June 5. In addition, Maxim Group initiated research coverage of the company on March 27. CEO John Yu highlighted progress in Phase 2 trials for ENV105 and advancements in its KROS platform as signs of growing momentum in oncology innovation.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company advancing targeted immunotherapies, has entered into a securities purchase agreement with a single institutional investor for a registered direct offering of 3,325,000 shares of common stock at $0.65 per share, or pre-funded warrants in lieu of stock. Concurrently, the company will issue series G warrants to purchase up to 6,053,000 shares of common stock in a private placement. The total gross proceeds from both transactions are expected to be approximately $3.9 million before fees and expenses. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent. Calidi plans to use the proceeds to support working capital, general corporate purposes and advancement of its clinical programs.

Aditxt (NASDAQ: ADTX), a social innovation platform focused on accelerating health technologies, announced that its latest Aditxt Weekly Update will spotlight the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. The proprietary technology, based on adductomics, is engineered to detect early DNA changes that could lead to cancer and other diseases. The discussion will emphasize how the CaSe Platform supports Pearsanta’s mission of advancing early detection and prevention in oncology. Featured participants include Dr. Shahrokh Shabahang of Aditxt, Chris Mitton of Pearsanta, and Dr. Roger Giese, the platform’s co-inventor.

Knightscope (NASDAQ: KSCP), a developer of autonomous security robots and AI technologies, has entered into definitive agreements to sell 625,000 shares of common stock at $2.75 per share in a registered direct offering, expected to close on or about March 31, 2025. Gross proceeds are anticipated to total approximately $1.7 million before fees and expenses. H.C. Wainwright & Co. is acting as the exclusive placement agent. Knightscope plans to use the net proceeds for working capital and general corporate purposes.

The International Energy Agency (IEA) has reported that soaring electricity demand in 2024 led to increased power generation from both renewable energy sources and fossil fuels. The agency attributes this surge to record-breaking temperatures, which spiked air conditioning use and significantly raised global energy consumption.